JB
GLUE icon

Julian Baker’s Monte Rosa Therapeutics GLUE Stock Holding History

Julian Baker’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$105M Hold
4,345,736
– – 0.53% 26
2026
Q1 		$71.5M Hold
4,345,736
– – 0.41% 32
2025
Q4 		$68.1M Sell
4,345,736
-570,359
-12% -$7.69M 0.4% 32
2025
Q3 		$36.4M Hold
4,916,095
– – 0.26% 37
2025
Q2 		$22.2M Hold
4,916,095
– – 0.22% 35
2025
Q1 		$22.8M Hold
4,916,095
– – 0.25% 32
2024
Q4 		$34.1M Hold
4,916,095
– – 0.36% 32
2024
Q3 		$26.1M Hold
4,916,095
– – 0.27% 37
2024
Q2 		$18.4M Hold
4,916,095
– – 0.24% 40
2024
Q1 		$34.7M Hold
4,916,095
– – 0.43% 33
2023
Q4 		$27.8M Hold
4,916,095
– – 0.32% 35
2023
Q3 		$23.5M Buy
4,916,095
+1,892,144
+63% +$12.2M 0.14% 35
2023
Q2 		$20.7M Buy
3,023,951
+2,648,856
+706% +$17.1M 0.12% 42
2023
Q1 		$2.92M Buy
+375,095
New +$2.61M 0.02% 83

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

Julian Baker's GLUE Position: Q2 2026 in Review

Julian Baker held its Monte Rosa Therapeutics (GLUE) position steady in Q2 2026 at 4,345,736 shares worth $105M. The position accounts for 0.53% of the portfolio, ranked #26.

Julian Baker first reported a position in GLUE in Q1 2023 and has held it in 14 quarters since. 191 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Julian Baker held 4,345,736 shares of Monte Rosa Therapeutics worth $105M as of Q2 2026.
  • Julian Baker left its Monte Rosa Therapeutics share count unchanged in Q2 2026.
  • Monte Rosa Therapeutics made up 0.53% of Julian Baker's portfolio in Q2 2026, its #26 holding.
  • Julian Baker first reported a position in Monte Rosa Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • 191 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.